PLSENasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
PULSE BIOSCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$47.55+3.12 (+7.02%)
Close on Oct 19, 2026
- Market cap
- $3.29B
- P/E (TTM)
- –
- Dividend yield
- –
PULSE BIOSCIENCES, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q2 25 | Q4 23 | Q3 23 | Q2 23 | Q1 23 | Q4 22 | Q3 22 | Q2 22 | Q1 22 | Q4 21 | Q3 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle Units Products [Member] | – | – | $0 | $0 | $0 | $0 | $7.00K | $0 | $56.00K | $77.00K | $145.00K | $84.00K | – | – |
| Systems Products [Member] | – | – | – | – | – | – | – | $0 | $209.00K | $367.00K | $699.00K | $490.00K | – | – |
| Product [Member] | – | – | – | – | $0 | $0 | – | $0 | $265.00K | $444.00K | $844.00K | $574.00K | – | – |
| System Products [Member] | – | – | $0 | $0 | $0 | $0 | – | $0 | $209.00K | $367.00K | – | – | – | – |
By region
| Revenue | Q2 26 | Q2 25 | Q4 23 | Q3 23 | Q2 23 | Q1 23 | Q4 22 | Q3 22 | Q2 22 | Q1 22 | Q4 21 | Q3 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America [Member] | – | – | $0 | $0 | $0 | $0 | – | $0 | $214.00K | $312.00K | $777.00K | $405.00K | – | – |
| Rest Of World [Member] | – | – | – | – | – | – | – | $0 | $51.00K | $132.00K | $67.00K | $169.00K | – | – |
| Rest of World [Member] | – | – | $0 | $0 | $0 | $0 | $0 | $0 | $51.00K | $132.00K | – | – | – | – |
From the segment and revenue-disaggregation notes of Pulse Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.